Business Context and Reporting Period
Company: Gossamer Bio, Inc. (Nasdaq: GOSS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing seralutinib, an inhaled small molecule inhibitor targeting PDGFR, CSF1R, and c-KIT pathways, for the treatment of pulmonary hypertension (PH), specifically pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). The company has no approved products and generates no product revenue.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 |
|---|---|---|
| Total Revenue | $114.7 | $0.0 |
| Net Loss | $(56.5) | $(179.8) |
| Research & Development Expenses | $138.5 | $135.3 |
| General & Administrative Expenses | $36.1 | $38.5 |
| Cash, Cash Equivalents & Marketable Securities | $294.5 | $296.4 |
| Long-Term Debt (2027 Convertible Notes) | $197.5 | $196.6 |
| Accumulated Deficit | $(1,268.6) | $(1,212.0) |
Note: Revenue in 2024 was driven entirely by a strategic collaboration agreement with Chiesi Farmaceutici S.p.A., including a $160.0 million upfront payment and cost-sharing reimbursements.
Material Changes vs. Prior Period
- Revenue Generation: The company transitioned from zero revenue in 2023 to $114.7 million in 2024, primarily due to the May 2024 collaboration with Chiesi. This included $90.7 million recognized from the sale of licenses and $24.0 million from research and development services.
- Net Loss Reduction: Net loss decreased significantly by $123.3 million (69%) year-over-year, from $179.8 million in 2023 to $56.5 million in 2024, largely offset by the new revenue stream.
- Debt Restructuring: The company terminated its Credit Facility with MidCap Financial Trust in May 2024, paying off the outstanding balance of approximately $7.7 million. The remaining debt consists of $200.0 million in aggregate principal of 5.00% Convertible Senior Notes due 2027.
- Operating Expenses: Total operating expenses decreased by $9.1 million to $174.6 million. While R&D expenses for seralutinib increased by $36.1 million, this was offset by a $32.9 million decrease in costs related to terminated programs.
Guidance, Outlook, and Risks
Outlook and Milestones
- PROSERA Study (PAH): The registrational Phase 3 PROSERA study is ongoing. Topline data is expected in the fourth quarter of 2025.
- PH-ILD Development: The company expects to activate clinical sites for a global registrational Phase 3 trial for PH-ILD in the second half of 2025.
- Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($294.5 million as of Dec 31, 2024) are sufficient to fund operations for at least the next 12 months.
Collaboration with Chiesi
Under the May 2024 agreement, Gossamer and Chiesi share development costs equally (except for the PROSERA study, funded solely by Gossamer) and will share U.S. commercial profits/losses equally. Chiesi holds exclusive rights to commercialize outside the U.S. Gossamer is eligible for up to $146.0 million in regulatory milestones and $180.0 million in sales milestones, plus mid-to-high teens percentage royalties on net sales outside the U.S.
Key Risks
- Clinical Trial Failure: The company's entire value proposition depends on the success of seralutinib in Phase 3 trials. Failure to meet primary endpoints would materially harm the business.
- Capital Requirements: Despite the Chiesi funding, the company expects to incur significant losses and will require additional financing to complete development and commercialization.
- Regulatory Uncertainty: Seralutinib is a combination product (drug and device), requiring coordination between FDA drug and device centers, which may delay approval.
- Intellectual Property: The company relies on licensed IP from Pulmokine (now a subsidiary of XOMA Royalty Corporation) and must meet diligence obligations to maintain rights.
Investor Verification Checklist
- PROSERA Trial Enrollment: Verify the current enrollment status and patient retention rates for the Phase 3 PAH trial to assess the likelihood of meeting the Q4 2025 data readout.
- Chiesi Cost-Sharing Mechanics: Confirm the specific accounting treatment and cash flow impact of the cost-sharing arrangement, particularly regarding the PROSERA study which remains Gossamer's sole responsibility.
- Convertible Note Conversion Triggers: Review the terms of the 2027 Convertible Senior Notes to understand potential dilution scenarios if the stock price exceeds 130% of the conversion price ($16.23).
- Patent Expiration Dates: Verify the expiration dates of the core patents licensed from Pulmokine (noted as not expiring before 2034/2037) to assess the duration of market exclusivity.
- PH-ILD Trial Design: Monitor the protocol design for the upcoming PH-ILD Phase 3 trial, as this represents a significant expansion of the addressable market.